How At-home Diagnostic Screening Detects Prostate Cancer

Prostate cancer screening has come on leaps and bounds over the last 15 years. Health screening plays a crucial role in the nation’s preventative healthcare.

The UKNSC’s decision not to introduce a national prostate cancer screening programme didn’t change the reality on the ground, and the consequences are measurable: more than 12,000 men annually die from prostate cancer – largely because the disease is diagnosed too late.

There is a clear solution, and waiting isn’t an option.

A recent case has captured national attention – four brothers from Lancashire were all diagnosed with prostate cancer within six months of each other – not because they were invited for screening, but because one brother got a PSA test (Prostate-Specific Antigen) and then encouraged the others to do the same. Due to this – all four were diagnosed early enough to receive effective treatment and have since been cleared.

Their story illustrates why a modern screening strategy must begin long before a man steps into a clinic.

Self‑sampling offers a solution – and RDi is already delivering at scale

RDi’s prostate self-sampling kits not only offer compliant and scalable sample collection, logistics and processing – but remove the largest barriers to early screening. Allowing users to collect samples within the comfort of their own homes, we can solve issues with appointments, travel, discomfort, and disengagement.

Being able to self-serve and self-sample lets men collect blood or saliva samples in minutes.

Add in robust digital infrastructure (that offers full chain‑of‑custody and end‑to‑end traceability) such as our +Cura solution, and we ensure that every single prostate test kit is part of a complete, governed and fully compliant pathway:

• Men can register, request, track and receive results within a single system, with no need to chase updates or navigate separate portals.
• Clinicians have full visibility across the pathway, reducing follow-ups, admin burden and missed results.
• Screening hubs can recall, refer or escalate within one digital journey, rather than juggling disconnected systems.
• Population-level data can help target high-risk groups and underserved regions, so resources go where they’re needed most.

It’s tried, tested and trusted – proven in our work delivering the national bowel screening programme, where we produce and allocate up to 40,000 kits per day, at national scale and without compromising quality or compliance.

Crucially self-sampling can fill the gap today, while TRANSFORM builds the evidence for tomorrow.

Even once the UKNSC has the evidence it needs, the infrastructure challenge won’t simply disappear. A modern screening programme cannot rely on traditional, clinic-first pathways. Capacity, geography and inequality make that impossible – and building that infrastructure from scratch, once policy demands it, will only slow things down further.

The future of screening will be:

Distributed

Diagnostics delivered where people are – at home, work and in communities – through self‑sampling, community pathways and remote access.

Digital

Automated follow‑up, results pathways, audit trails and recall systems that can scale nationally without manual bottlenecks.

Diverse

Flexible enough to incorporate multiple testing pathways – whatever the evidence proves most effective.

RDi already operates at this intersection: manufacturing, logistics, compliance, data, digital triage and patient engagement in one seamless, integrated ecosystem.

Conclusion: We can close the screening gap now

The absence of a national prostate cancer screening programme shouldn’t mean the absence of early detection. TRANSFORM will shape the future, but millions of men living in the present face a system with a missing pathway – and every year of delay carries a real cost.

Self-sampling is the bridge. It’s scalable, low-burden, cost-efficient and ready today, with the infrastructure already built to support it at national scale.

We’re committed to helping the NHS, private healthcare providers and retailers close the prostate screening gap immediately – and when a national programme finally arrives, the infrastructure will already be in place to deliver it, at pace and without a standing start.

Because the pathway shouldn’t start when the policy does.

It should start now.

To contact the RDi team, please click the button below and find out how we can assist screening programmes and connect the pathway for your patients.